Show simple item record

dc.contributor.authorLinton, K. M.
dc.contributor.authorWahlin, B.
dc.contributor.authorLeppa, S.
dc.contributor.authorMorschhauser, F.
dc.contributor.authorElliott, B.
dc.contributor.authorLiu, T.
dc.contributor.authorStirner, M. C.
dc.contributor.authorAbbas, A.
dc.contributor.authorFalchi, L.
dc.date.accessioned2022-04-28T13:57:40Z
dc.date.available2022-04-28T13:57:40Z
dc.date.issued2022en
dc.identifier.citationLinton KM, Wahlin B, Leppa S, Morschhauser F, Elliott B, Liu T, et al. Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results. British Journal of Haematology. 2022;197:94-.en
dc.identifier.urihttp://hdl.handle.net/10541/625153
dc.language.isoenen
dc.titleSubcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Resultsen
dc.typeMeetings and Proceedingsen
dc.identifier.journalBritish Journal of Haematologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record